<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373137</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00010818</org_study_id>
    <nct_id>NCT02373137</nct_id>
  </id_info>
  <brief_title>Descemets Endothelial Thickness Comparison Trial</brief_title>
  <acronym>DETECT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Winston Chamberlain, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare visual acuity outcomes of two types of endothelial
      keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2)
      Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be
      randomized to have DSAEK and the other half will have DMEK.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corneal transplantation has evolved rapidly in recent years. Lamellar keratoplasty to replace
      diseased endothelium has led to faster recovery times, fewer complications, and better visual
      acuity outcomes. Currently, Descemet's Stripping Endothelial Keratoplasty (DSAEK) is the most
      common procedure because of its relative ease and good outcomes. Newer techniques such as
      Descemet's Membrane Endothelial Keratoplasty (DMEK), where Descemet's membrane alone is
      transplanted, has the potential to further improve visual acuity outcomes, produce fewer
      higher-order corneal aberrations and decrease rejection rates. However, donor preparation,
      increased intra-operative times, and problems with donor attachment in DMEK are all important
      limitations.

      There are three potential mechanisms by which DMEK may provide better visual acuity outcomes
      than DSAEK; graft thickness, interface haze and corneal higher-order aberrations. Graft
      thickness has been correlated with best spectacle corrected visual acuity (BSCVA) outcomes
      among thinner grafts. One retrospective case series found that 71% of thin endothelial grafts
      (defined as &lt;131μm) had BSCVA of 20/25 or better while only 50% of thick grafts (defined as
      ≥131) achieved this. In addition, higher-order aberrations, in particular of the posterior
      cornea, are increased after DSAEK. Theoretically, given the decreased tissue transplanted
      after DMEK this would be lessened, however, one retrospective series looking at higher order
      aberrations in DMEK compared with DSAEK found no difference in posterior aberrations of the
      central 4.0 mm zone between the two groups. Finally, interface haze may be increased in DSAEK
      and has been correlated with BSCVA.

      Ultrathin DSAEK involves donor preparation with a deep microkeratome pass to produce donor
      grafts less than 100 um thick. This procedure may have similar results to DMEK but without
      the technical difficulties. Several large prospective series show similar visual outcome
      results and rates of immunologic rejection between ultrathin DSAEK and DMEK, however
      comparisons are difficult. This comparative effectiveness clinical trial could directly
      address these important issues. The investigators also anticipate that secondary analyses of
      the trial data will allow us to address several more.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial Cell Count</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Higher-Order Aberrations</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>As measured by Pentacam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interface Haze</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>As measured by Pentacam densitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Eye Institute - Visual Functioning Questionnaire (NEI-VFQ)</measure>
    <time_frame>Baseline, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Failure/Graft Rejection</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>composite measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Spectacle-Corrected Visual Acuity</measure>
    <time_frame>3, 12, 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Refraction</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>Manifest refraction using phoropter</description>
  </other_outcome>
  <other_outcome>
    <measure>Graft Thickness</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>As measured by Optical coherence tomography (OCT) and Pachymetry</description>
  </other_outcome>
  <other_outcome>
    <measure>Operative times</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events/Complication rates</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>composite measure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Keratoplasty</condition>
  <condition>Grafting, Corneal</condition>
  <condition>Transplantation, Corneal</condition>
  <condition>Transplantation, Cornea</condition>
  <condition>Keratoplasty, Lamellar</condition>
  <arm_group>
    <arm_group_label>DSAEK</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMEK</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DSAEK</intervention_name>
    <arm_group_label>DSAEK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DMEK</intervention_name>
    <arm_group_label>DMEK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoserter</intervention_name>
    <description>The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.</description>
    <arm_group_label>DSAEK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone is a corticosteroid used to alleviate swelling post-surgery.</description>
    <arm_group_label>DSAEK</arm_group_label>
    <arm_group_label>DMEK</arm_group_label>
    <other_name>Millipred</other_name>
    <other_name>Orapred</other_name>
    <other_name>Omnipred</other_name>
    <other_name>Econopred</other_name>
    <other_name>Flo-Pred</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofloxacin</intervention_name>
    <description>Ofloxacin is an antibiotic used to treat bacterial infections of the eye.</description>
    <arm_group_label>DSAEK</arm_group_label>
    <arm_group_label>DMEK</arm_group_label>
    <other_name>Ocuflox</other_name>
    <other_name>Floxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tropicamide</intervention_name>
    <description>Tropicamide is a prescription drug used to dilate pupils during an eye exam.</description>
    <arm_group_label>DSAEK</arm_group_label>
    <arm_group_label>DMEK</arm_group_label>
    <other_name>Mydriacyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Phenylephrine is a prescription drug used to dilate pupils during an eye exam.</description>
    <arm_group_label>DSAEK</arm_group_label>
    <arm_group_label>DMEK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Jones Tube</intervention_name>
    <description>The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.</description>
    <arm_group_label>DMEK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Damaged or diseased endothelium from Fuchs or Pseudophakic Bullous Keratopathy

          -  Good candidates for corneal transplantation for either DMEK or DSAEK

          -  Willingness and ability to undergo a cornea transplantation

          -  Willingness to participate in follow-up visits

        Exclusion Criteria:

          -  Participants who are decisionally and/or cognitively impaired

          -  Participants who are not suitable for the DMEK or DSAEK surgeries

          -  Prior Endothelial Keratoplasty (EK) or any other ophthalmic surgery except
             uncomplicated cataract surgery

          -  Indication for surgery that is not suitable for EK (e.g. keratoconus, stromal
             dystrophies and scars)

          -  Presence of a condition that increases the probability for failure (e.g., heavily
             vascularized cornea, uncontrolled uveitis)

          -  Other primary endothelial dysfunction conditions including posterior polymorphous
             corneal dystrophy and congenital hereditary corneal dystrophy

          -  Aphakia, or anterior chamber intraocular lens (IOL) in study eye prior to or
             anticipated during EK

          -  Planned intraocular lens exchange of an anterior chamber IOL with a posterior chamber
             IOL in study at time of study EK

          -  Pre-operative central sub-epithelial or stromal scarring that the investigator
             believes is visually significant and could impact post-operative stromal clarity
             assessment

          -  Peripheral anterior synechiae (iris to angle) in the angle greater than a total of
             three clock hours

          -  Hypotony (Intraocular pressure &lt;10mmHg)

          -  Uncontrolled (defined as intraocular pressure &gt;25mmHg) glaucoma Visually significant
             optic nerve or macular pathology

          -  Visually significant optic nerve or macular pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winston Chamberlain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Rose-Nussbaumer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Byers Eye Institute, Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>F. I. Proctor Foundation, University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute, Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Price FW Jr, Price MO. Evolution of endothelial keratoplasty. Cornea. 2013 Nov;32 Suppl 1:S28-32. doi: 10.1097/ICO.0b013e3182a0a307. Review.</citation>
    <PMID>24104929</PMID>
  </reference>
  <reference>
    <citation>Chen ES, Terry MA, Shamie N, Hoar KL, Friend DJ. Descemet-stripping automated endothelial keratoplasty: six-month results in a prospective study of 100 eyes. Cornea. 2008 Jun;27(5):514-20. doi: 10.1097/ICO.0b013e3181611c50.</citation>
    <PMID>18520497</PMID>
  </reference>
  <reference>
    <citation>Ham L, Dapena I, van Luijk C, van der Wees J, Melles GR. Descemet membrane endothelial keratoplasty (DMEK) for Fuchs endothelial dystrophy: review of the first 50 consecutive cases. Eye (Lond). 2009 Oct;23(10):1990-8. doi: 10.1038/eye.2008.393. Epub 2009 Jan 30.</citation>
    <PMID>19182768</PMID>
  </reference>
  <reference>
    <citation>Dirisamer M, van Dijk K, Dapena I, Ham L, Oganes O, Frank LE, Melles GR. Prevention and management of graft detachment in descemet membrane endothelial keratoplasty. Arch Ophthalmol. 2012 Mar;130(3):280-91. doi: 10.1001/archophthalmol.2011.343. Epub 2011 Nov 14.</citation>
    <PMID>22084160</PMID>
  </reference>
  <reference>
    <citation>Kruse FE, Laaser K, Cursiefen C, Heindl LM, Schlötzer-Schrehardt U, Riss S, Bachmann BO. A stepwise approach to donor preparation and insertion increases safety and outcome of Descemet membrane endothelial keratoplasty. Cornea. 2011 May;30(5):580-7.</citation>
    <PMID>21598430</PMID>
  </reference>
  <reference>
    <citation>Rudolph M, Laaser K, Bachmann BO, Cursiefen C, Epstein D, Kruse FE. Corneal higher-order aberrations after Descemet's membrane endothelial keratoplasty. Ophthalmology. 2012 Mar;119(3):528-35. doi: 10.1016/j.ophtha.2011.08.034. Epub 2011 Dec 22.</citation>
    <PMID>22197439</PMID>
  </reference>
  <reference>
    <citation>Busin M, Madi S, Santorum P, Scorcia V, Beltz J. Ultrathin descemet's stripping automated endothelial keratoplasty with the microkeratome double-pass technique: two-year outcomes. Ophthalmology. 2013 Jun;120(6):1186-94. doi: 10.1016/j.ophtha.2012.11.030. Epub 2013 Mar 1.</citation>
    <PMID>23466268</PMID>
  </reference>
  <reference>
    <citation>Guerra FP, Anshu A, Price MO, Giebel AW, Price FW. Descemet's membrane endothelial keratoplasty: prospective study of 1-year visual outcomes, graft survival, and endothelial cell loss. Ophthalmology. 2011 Dec;118(12):2368-73. doi: 10.1016/j.ophtha.2011.06.002. Epub 2011 Aug 27.</citation>
    <PMID>21872938</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Winston Chamberlain, MD, PhD</investigator_full_name>
    <investigator_title>Ophthalmologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Tropicamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

